Celcuity Inc. Common Stock
CELC
CELC: Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
moreShow CELC Financials
Recent trades of CELC by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CELC's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of preparing a primary cell sample Feb. 28, 2023
-
Patent Title: Methods of measuring signaling pathway activity for selection of therapeutic agents May. 17, 2022
-
Patent Title: Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent Jul. 27, 2021
-
Patent Title: Whole cell assays and methods Apr. 13, 2021
-
Patent Title: Whole cell assays and methods Aug. 07, 2018
-
Patent Title: Whole cell assays and methods Aug. 02, 2016
Federal grants, loans, and purchases
Followers on CELC's company Twitter account
Number of mentions of CELC in WallStreetBets Daily Discussion
Recent insights relating to CELC
Recent picks made for CELC stock on CNBC
ETFs with the largest estimated holdings in CELC
Flights by private jets registered to CELC